|
|
|
|
||
UPenn Pioneer Bruce Levine on CAR-T Treatment in 2023 BMY's capacity growth for both Abecma/Ide-cel and Breyanzi/Liso-cel in addition to positive earlier line data for both products and positive top-line CLL Breyanzi data should help drive sales. |
return to message board, top of board |